Ubs Group Ag Annexon, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Annexon, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 75,573 shares of ANNX stock, worth $531,278. This represents 0.0% of its overall portfolio holdings.

Number of Shares

75,573

Previous 91,046 16.99%

Holding current value

$531,278

Previous $652,000 43.25%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.33 - $6.79 $66,998 - $105,061	-15,473 Reduced 16.99%	75,573 $370,000
Q1 2024 May 13, 2024	BUY	$4.03 - $7.81 $167,083 - $323,802	41,460 Added 83.61%	91,046 $652,000
Q4 2023 Feb 09, 2024	BUY	$1.63 - $4.63 $40,647 - $115,458	24,937 Added 101.17%	49,586 $225,000
Q3 2023 Nov 09, 2023	SELL	$2.13 - $3.84 $4,860 - $8,762	-2,282 Reduced 8.47%	24,649 $58,000
Q2 2023 Aug 11, 2023	BUY	$2.1 - $6.37 $56,555 - $171,550	26,931 New	26,931 $94,000
Q4 2022 Feb 08, 2023	BUY	$4.56 - $6.61 $5,517 - $7,998	1,210 Added 41.87%	4,100 $21,000
Q3 2022 Nov 10, 2022	SELL	$3.75 - $6.63 $324,802 - $574,250	-86,614 Reduced 96.77%	2,890 $18,000
Q2 2022 Aug 10, 2022	BUY	$2.11 - $4.06 $188,853 - $363,386	89,504 New	89,504 $338,000
Q1 2022 May 16, 2022	SELL	$2.73 - $11.94 $147,818 - $646,503	-54,146 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.49 - $22.0 $622,137 - $1.19 Million	54,146 New	54,146 $622,000
Q2 2021 Aug 13, 2021	SELL	$17.81 - $27.48 $6,482 - $10,002	-364 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$22.0 - $35.01 $184,866 - $294,189	-8,403 Reduced 95.85%	364 $10,000
Q4 2020 Feb 11, 2021	BUY	$20.81 - $30.55 $174,658 - $256,406	8,393 Added 2244.12%	8,767 $219,000
Q3 2020 Nov 12, 2020	BUY	$17.5 - $30.23 $6,545 - $11,306	374 New	374 $11,000

Others Institutions Holding ANNX

# of Institutions

156

Shares Held

101M

Call Options Held

3.73M

Put Options Held

1.3M

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $335M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account